Elske Hoornenborg1, Roel C A Achterbergh, Maarten F Schim van der Loeff, Udi Davidovich, Arjan Hogewoning, Henry J C de Vries, Janke Schinkel, Maria Prins, Thijs J W van de Laar. 1. aDepartment of Infectious Diseases, Research and Prevention, Public Health Service of Amsterdam bDepartment of Infectious Diseases, Clinic for Sexually Transmitted Infections, Public Health Service of Amsterdam cDepartment of Infectious Diseases, Academic Medical Center, Center for Immunity and Infection Amsterdam (CINIMA), University of Amsterdam dDepartment of Dermatology, Academic Medical Center, Amsterdam eNational Institute of Public Health and the Environment, Center for Infectious Disease Control, Bilthoven fDepartment of Medical Microbiology, Academic Medical Center, Clinical Virology Laboratory gSanquin Research, Department of Blood-borne Infections, Amsterdam, The Netherlands. *Maria Prins and Thijs J.W. van de Laar attributed equally to the article.
Abstract
OBJECTIVES AND DESIGN: Hepatitis C virus (HCV) has been recognized as an emerging sexually transmitted infection (STI) among HIV-positive MSM. However, HIV-negative MSM at high risk for HIV might also be at increased risk for HCV. We studied the HCV prevalence in HIV-negative MSM who start preexposure prophylaxis (PrEP) in Amsterdam. Phylogenetic analysis was used to compare HCV strains obtained from HIV-negative and HIV-positive MSM. METHODS: At enrolment in the Amsterdam PrEP demonstration project, HIV-negative MSM were tested for the presence of HCV antibodies and HCV RNA. If positive for HCV RNA, an HCV NS5B gene fragment (709 bp) was sequenced and compared with HCV isolates from HIV-positive MSM (n = 223) and risk groups other than MSM (n = 153), using phylogenetic analysis. RESULTS: Of 375 HIV-negative MSM enrolled in Amsterdam PrEP, 18 (4.8%, 95% confidence interval 2.9-7.5%) of participants were anti-HCV and/or HCV RNA positive at enrolment; 15 of 18 (83%) had detectable HCV RNA. HCV genotyping showed genotype 1a (73%), 4d (20%), and 2b (7%). All HCV-positive MSM starting PrEP were part of MSM-specific HCV clusters containing MSM with and without HIV. CONCLUSION: HCV prevalence among HIV-negative MSM who started PrEP was higher than previously reported. All HIV-negative HCV-positive MSM were infected with HCV strains already circulating among HIV-positive MSM. The increasing overlap between sexual networks of HIV-positive and HIV-negative MSM might result in an expanding HCV-epidemic irrespective of HIV-status. Hence, routine HCV testing should be offered to MSM at high risk for HIV, especially for those enrolling in PrEP programs.
OBJECTIVES AND DESIGN:Hepatitis C virus (HCV) has been recognized as an emerging sexually transmitted infection (STI) among HIV-positive MSM. However, HIV-negative MSM at high risk for HIV might also be at increased risk for HCV. We studied the HCV prevalence in HIV-negative MSM who start preexposure prophylaxis (PrEP) in Amsterdam. Phylogenetic analysis was used to compare HCV strains obtained from HIV-negative and HIV-positive MSM. METHODS: At enrolment in the Amsterdam PrEP demonstration project, HIV-negative MSM were tested for the presence of HCV antibodies and HCV RNA. If positive for HCV RNA, an HCV NS5B gene fragment (709 bp) was sequenced and compared with HCV isolates from HIV-positive MSM (n = 223) and risk groups other than MSM (n = 153), using phylogenetic analysis. RESULTS: Of 375 HIV-negative MSM enrolled in Amsterdam PrEP, 18 (4.8%, 95% confidence interval 2.9-7.5%) of participants were anti-HCV and/or HCV RNA positive at enrolment; 15 of 18 (83%) had detectable HCV RNA. HCV genotyping showed genotype 1a (73%), 4d (20%), and 2b (7%). All HCV-positive MSM starting PrEP were part of MSM-specific HCV clusters containing MSM with and without HIV. CONCLUSION:HCV prevalence among HIV-negative MSM who started PrEP was higher than previously reported. All HIV-negative HCV-positive MSM were infected with HCV strains already circulating among HIV-positive MSM. The increasing overlap between sexual networks of HIV-positive and HIV-negative MSM might result in an expanding HCV-epidemic irrespective of HIV-status. Hence, routine HCV testing should be offered to MSM at high risk for HIV, especially for those enrolling in PrEP programs.
Authors: Massimo Andreoni; Sergio Babudieri; Savino Bruno; Massimo Colombo; Anna L Zignego; Vito Di Marco; Giovanni Di Perri; Carlo F Perno; Massimo Puoti; Gloria Taliani; Erica Villa; Antonio Craxì Journal: Infection Date: 2017-11-02 Impact factor: 3.553
Authors: Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2018-07-24 Impact factor: 56.272
Authors: Margaret Hellard; Sophia E Schroeder; Alisa Pedrana; Joseph Doyle; Campbell Aitken Journal: Cold Spring Harb Perspect Med Date: 2020-04-01 Impact factor: 6.915
Authors: Lisa Steininger; David Chromy; David Bauer; Benedikt Simbrunner; Teresa Binter; Philipp Schwabl; Caroline Schmidbauer; Michael Trauner; Michael Gschwantler; Mattias Mandorfer; Thomas Reiberger Journal: Wien Klin Wochenschr Date: 2020-12-22 Impact factor: 1.704
Authors: Risha Irvin; Theresa Gamble; Jowanna Malone; Zhe Wang; Ethan Wilson; James P Hughes; Jason Farley; Kenneth H Mayer; Carlos Del Rio; D Scott Batey; Vanessa Cummings; Robert H Remien; Chris Beyrer; Chloe L Thio Journal: Clin Infect Dis Date: 2021-10-05 Impact factor: 20.999
Authors: Elske Hoornenborg; Roel Ca Achterbergh; Maarten F Schim van der Loeff; Udi Davidovich; Jannie J van der Helm; Arjan Hogewoning; Yvonne Thp van Duijnhoven; Gerard Jb Sonder; Henry Jc de Vries; Maria Prins Journal: J Int AIDS Soc Date: 2018-03 Impact factor: 5.396